Biomarkers of Human Longevity
by Dmitry Kaminskiy. Data Science for Accelerating Aging Research and R&D The Critical Catalyst for Practical Human Longevity Tangible Investment Decision Making
There is perhaps no other single technology or industry subsector, with the exception of AI, that has more potential to accelerate the realization of real-world impacts in Longevity across the full scope of its sectors and domains - industry, policy, investment, entrepreneurship, policy, and governance - than Biomarkers of Human Longevity.
Given the unique confluence of Biomarkers of Human Longevity’s disruptive impact and accelerative potential, on the one hand, and the high degree of disharmonization in terms of what they are and how they could and should be used, on the other hand, it is clear to me that there is a pressing unmet need for the production of a dedicated book that takes Biomarkers of Longevity as its central concern and major fulcrum, identifying the true potential that this technology has to increase individual and national Health-Adjusted Life Expectancy (HALE) and Quality-Adjusted Life Expectancy (QALY), optimize strategic decision-making for start-ups and corporations, de-risk investment, provide for the first time a tangible framework for company valuation, due diligence based on human validation, enable reliable forecasting clinical outcomes, serve as an effective platform for safe self-experimentation and personalized therapeutic fine-tuning, and pave the way for a much more tangible, stable and scalable Global Longevity Industry, where Longevity’s socially-inclusive humanitarian impact is maximized and its potential ethical and socio-economic concerns are neutralized.
Visit website: https://www.longevity-book.com/biomarkers
See also: Dmitry Kaminskiy - Managing partner at Deep Knowledge Ventures